There is mounting evidence to implicate complex atherosclerotic aortic plaq
ues as a significant independent risk factor for embolic stroke. Ulcerated
plaques at autopsy, plaques thicker than 4 to 5mm at transesophageal echoca
rdiography and those with mobile components are more likely to be associate
d with stroke. Mobile thrombus in the lumen may be a source of cerebral emb
oli. Among patients with ischemic stroke, those with plaques thicker than 4
mm in the aortic arch have the highest risk of recurrent stroke, myocardial
infarction, other vascular event including vascular death. However, since
no randomized trials have been conducted to evaluate the role of any antith
rombotic therapies in patients with aortic atheroma, no recommendation can
be made regarding the best treatment strategies. Antiplatelet agents, oral
anticoagulant, thrombolytic therapy, and elective surgical endarterectomy o
r graft replacement are all reasonable options that have been proposed and
that must be evaluated in term of benefit/risks ratio in specific randomize
d controlled trials. Meanwhile, antiplatelet agents and aggressive risk fac
tor management appear to be the first line treatment. No recommendation can
be made to use oral anticoagulation in these patients nor for a target INR
. Concerns also exist on the possibility of anticoagulation driven choleste
rol embolism in these patients.